http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
-
Abivax (ABVX) Announces Board Changes
-
Abivax Announces a Change to the Composition of its Board of Directors
-
Abivax presents third quarter 2024 key financial information
-
Abivax (ABVX) Appoints Mark Stenhouse as Board Observer
-
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
-
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
-
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
-
Abivax (ABVX) Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod
-
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
-
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
-
Abivax (ABVX) Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod
-
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD)
-
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
-
Abivax (ABVX) Provides Operational and Key Program Update
-
Abivax Provides Operational and Key Program Update
-
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
-
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
-
Abivax: 2020 Financial Communication Calendar
-
Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and Provides a Progress Update of the ABX464 Clinical Develo
-
ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference
-
ABIVAX Announces That It Has Been Selected to Present a Late-Breaking Abstract on ABX464 in Ulcerative Colitis at UEG Week 2019
-
ABIVAX Announces the Release of Its 2019 Half-year Financial Report
-
ABIVAX First-Half 2019 Financial Results and Operations Update
-
First Patient Enrolled in Abivax ABX464-103 Phase 2b Clinical Trial in Patients with Ulcerative Colitis
-
Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464
-
ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price
-
Abivax Receives First Clinical Trial Authorization for ABX464 Phase 2a Study in Patients with Rheumatoid Arthritis
-
Abivax Delivered Oral Presentation at Leading US International Gastroenterology Conference on ABX464 Phase 2a Nine-month Maintenance Data Demonstrating Long Term Efficacy and Safety in Ulcerative Coli
-
Abivax and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clinical Trial with ABX196 in Patients with Hepatocellular Carcinoma
-
Abivax Receives First Phase 2b Ulcerative Colitis Clinical Trial Authorization, Provides Update on Progress of ABX464 Clinical Development Plan in Inflammatory Diseases
-
Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn’s and Colitis Organisation (ECCO)
-
Abivax to Present Latest Clinical and Mechanism of Action Data on its Lead Compound ABX464 at Two Upcoming Conferences
-
Abivax Publishes in Nature Scientific Reports ABX464's Unique Mechanism of Action Leading to Both Anti-Inflammatory and Antiviral Effects
-
Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis
-
Abivax’s Phase 2a Ulcerative Colitis Clinical Trial Data Selected for Oral Plenary Presentation at 14th Congress of European Crohn’s and Colitis Organisation
-
Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients
-
Abivax KOL event today in Paris on ABX464 therapeutic-candidate in mid-stage clinical testing for ulcerative colitis and HIV
-
Abivax First-Half 2018 Financial Results and Operations Update
-
Abivax reports impressive results in clinical phase 2a trial of ABX464 as an oral treatment for ulcerative colitis patients
-
Abivax Presents ABX464 Mechanism of Action Data at the 22nd International AIDS Conference (AIDS 2018)
-
ABIVAX Secures up to EUR 20m Debt Financing from Kreos Capital
-
Abivax Sponsors Prize for HIV Cure Projects
-
Abivax (ABVX) Reports Completes Dosing in Phase 2a Proof-of-Concept Clinical Trial of ABX464 in Ulcerative Colitis (ABX464-101)
-
Abivax Completes Dosing in Phase 2a Proof-of-Concept Clinical Trial of ABX464 in Ulcerative Colitis (ABX464-101)
-
Abivax Releases Positive Top Line Data from ABX464-005 Phase 2a Study in HIV Infection
-
Abivax Appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member
-
ABIVAX Presents New Data on ABX464 Mechanism of Action at 16th European Meeting on HIV & Hepatitis
-
Abivax Completes Enrolment of Phase IIa Clinical Trial of ABX464 to Treat Patients with Ulcerative Colitis
-
ABIVAX Announces the Publication of Its 2018 Registration Document
